[Zurück]
 
Bitte auswählen
Jahr
Details
Sprache
Sortierung
Ausgabe
neu: RTF !
 Forschungsbericht für das Jahr 2018

Department Innere Medizin

Klinik für Innere Medizin I

Hugstetter Str. 55
79106 Freiburg
Tel: 0761/270-34060 Fax: 0761/270-32060
https://www.uniklinik-freiburg.de/medizin1.html


Einträge in der Rubrik "Who is Who"

Wissenschaftliche Publikationen

Originalarbeiten in wissenschaftlichen Fachzeitschriften:
  • Arends J: How to feed patients with gastrointestinal mucositis. Curr Opin Support Pa, 2018; 12 (2): 168-173. : http://dx.doi.org/10.1097/SPC.0000000000000345
  • Arends J: Struggling with nutrition in patients with advanced cancer: nutrition and nourishment-focusing on metabolism and supportive care. Ann Oncol, 2018; 29 (suppl_2): ii27-ii34. : http://dx.doi.org/10.1093/annonc/mdy093
  • Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S: Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. Ann Hematol, 2018; 97 (10): 1785-1795. : http://dx.doi.org/10.1007/s00277-018-3396-4
  • Brandt LP, Albers J, Hejhal T, Pfundstein S, Goncalves AF, Catalano A, Wild PJ, Frew IJ: Mouse genetic background influences whether Hras(G12V) expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. Oncotarget, 2018; 9 (28): 19753-19766. : http://dx.doi.org/10.18632/oncotarget.24831
  • Brauns-Schubert P, Schubert F, Wissler M, Weiss M, Schlicher L, Bessler S, Safavi M, Miething C, Borner C, Brummer T, Maurer U: CDK9-mediated phosphorylation controls the interaction of TIP60 with the transcriptional machinery. Embo Rep, 2018; 19 (2): 244-256. : http://dx.doi.org/10.15252/embr.201744311
  • Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, Cassinotti A, Satsangi J, Kazmi M, Lopez-Sanroman A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA: Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation. J Crohns Colitis, 2018; 12 (9): 1097-1103. : http://dx.doi.org/10.1093/ecco-jcc/jjy069
  • Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosinol L: Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol, 2018; 11 (1): 10-10. : http://dx.doi.org/10.1186/s13045-017-0549-1
  • Chen S, Zeiser R: The Role of MicroRNAs in Myeloid Cells during Graft-versus-Host Disease. Front Immunol, 2018; 9: 4-4. : http://dx.doi.org/10.3389/fimmu.2018.00004
  • Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J: Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transpl, 2018; 53 (5): 565-575. : http://dx.doi.org/10.1038/s41409-017-0021-4
  • de van der Schueren MAE, Laviano A, Blanchard H, Jourdan M, Arends J, Baracos VE: Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol, 2018; 29 (5): 1141-1153. : http://dx.doi.org/10.1093/annonc/mdy114
  • Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wasch R, Bertz H, Muller-Quernheim J, Finke J, Marks R, Prasse A: Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced intensity conditioning. Biol Blood Marrow Tr, 2018 (online). : http://dx.doi.org/10.1016/j.bbmt.2018.06.024
  • Duque-Afonso J, Lin CH, Han K, Morgens DW, Jeng EE, Weng Z, Jeong J, Wong SHK, Zhu L, Wei MC, Chae HD, Schrappe M, Cario G, Duyster J, Sakamoto KM, Bassik MC, Cleary ML: CBP modulates sensitivity to dasatinib in pre-BCR+ acute lymphoblastic leukemia. Cancer Res, 2018. : http://dx.doi.org/10.1158/0008-5472.CAN-18-1703 (in Druck)
  • Duque-Afonso J, Waterhouse M, Pfeifer D, Follo M, Duyster J, Bertz H, Finke J: Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation. Clin Biochem, 2018; 52: 137-141. : http://dx.doi.org/10.1016/j.clinbiochem.2017.11.015
  • Engelhardt M, Herget GW, Graziani G, Ihorst G, Reinhardt H, Ajayi S, Knop S, Wasch R: Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica, 2018; 103 (5): 755-758. : http://dx.doi.org/10.3324/haematol.2018.188516
  • Felip E, Hirsh V, Popat S, Cobo M, Fulop A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM: Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clin Lung Cancer, 2018; 19 (1): 74-83e11. : http://dx.doi.org/10.1016/j.cllc.2017.06.002
  • Fuerst D, Frank S, Mueller C, Beelen DW, Schetelig J, Niederwieser D, Finke J, Bunjes D, Kroger N, Neuchel C, Tsamadou C, Schrezenmeier H, Beyersmann J, Mytilineos J: Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. Haematologica, 2018; 103 (9): 1527-1534. : http://dx.doi.org/10.3324/haematol.2017.183012
  • Ganier O *, Schnerch D *, Nigg EA: Structural centrosome aberrations sensitize polarized epithelia to basal cell extrusion. Open Biol, 2018; 8 (6) (online). : http://dx.doi.org/10.1098/rsob.180044
  • Ganier O *, Schnerch D *, Oertle P, Lim RY, Plodinec M, Nigg EA: Structural centrosome aberrations promote non-cell-autonomous invasiveness. Embo J, 2018; 37 (9): e98576. : http://dx.doi.org/10.15252/embj.201798576
  • Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poire X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kroger N: Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. Biol Blood Marrow Tr, 2018; 24 (3): 507-513. : http://dx.doi.org/10.1016/j.bbmt.2017.11.017
  • Gay F, Engelhardt M, Terpos E, Wasch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kroger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P: From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018; 103 (2): 197-211. : http://dx.doi.org/10.3324/haematol.2017.174573
  • Gengenbach L, Reinhardt H, Ihorst G, Ajayi S, Dold SM, Kohler M, Einsele H, Duyster J, Wasch R, Engelhardt M: Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials(). Leukemia Lymphoma, 2018 (online): 1-8. : http://dx.doi.org/10.1080/10428194.2018.1448084
  • Gerboth S, Frittoli E, Palamidessi A, Baltanas FC, Salek M, Rappsilber J, Giuliani C, Troglio F, Rolland Y, Pruneri G, Kreutmair S, Pallavicini I, Zobel M, Cinquanta M, Minucci S, Gomez C, Santos E, Illert AL, Scita G: Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. Leukemia, 2018; 32 (3): 820-827. : http://dx.doi.org/10.1038/leu.2017.267
  • Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wasch R: Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica, 2018. : http://dx.doi.org/10.3324/haematol.2018.200881 (in Druck)
  • Greil C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, Kuhbach K, Bosse R, Duyster J, Engelhardt M, Wasch R: Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. Leukemia Lymphoma, 2018; 59 (7): 1722-1725. : http://dx.doi.org/10.1080/10428194.2017.1393673
  • Hottenrott T *, Schorb E *, Fritsch K, Dersch R, Berger B, Huzly D, Rauer S, Tebartz van Elst L, Endres D, Stich O: The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis. J Neurol, 2018; 265 (5): 1106-1114. : http://dx.doi.org/10.1007/s00415-018-8779-x
  • Hulsdunker J, Ottmuller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, Follo M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lammermann T, Blaser MJ, Fife BT, Blazar BR, Beilhack A, Hill GR, Hacker G, Zeiser R: Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood, 2018; 131 (16): 1858-1869. : http://dx.doi.org/10.1182/blood-2017-10-812891
  • Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV: Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy-uk, 2018; 10 (5): 391-402. : http://dx.doi.org/10.2217/imt-2017-0156
  • Kern WV, Weber S, Dettenkofer M, Kaier K, Bertz H, Behnke M, Weisser M, Gotting T, Widmer AF, Theilacker C: Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. J Infection, 2018; 77 (1): 68-74. : http://dx.doi.org/10.1016/j.jinf.2018.05.004
  • Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M: Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. Jama Oncol, 2018; 4 (9): 1245-1253. : http://dx.doi.org/10.1001/jamaoncol.2018.2091
  • Klett H, Fuellgraf H, Levit-Zerdoun E, Hussung S, Kowar S, Kusters S, Bronsert P, Werner M, Wittel U, Fritsch R, Busch H, Boerries M: Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Front Genet, 2018; 9: 108-108. : http://dx.doi.org/10.3389/fgene.2018.00108
  • Klump J, Philipp U, Follo M, Eremin A, Lehmann H, Nestel S, von Bubnoff N, Nazarenko I: Extracellular Vesicles or free circulating DNA: where to search for BRAF and cKIT mutations? Nanomed-nanotechnol, 2018; 14 (3): 875-882. : http://dx.doi.org/10.1016/j.nano.2017.12.009
  • Kneis S, Wehrle A, Ilaender A, Volegova-Neher N, Gollhofer A, Bertz H: Results From a Pilot Study of Handheld Vibration: Exercise Intervention Reduces Upper-Limb Dysfunction and Fatigue in Breast Cancer Patients Undergoing Radiotherapy: VibBRa Study. Integr Cancer Ther, 2018; 17 (3): 717-727. : http://dx.doi.org/10.1177/1534735418766615
  • Kohler M, Greil C, Hudecek M, Lonial S, Raje N, Wasch R, Engelhardt M: Current developments in immunotherapy in the treatment of multiple myeloma. Cancer Cytopathol, 2018; 124 (10): 2075-2085. : http://dx.doi.org/10.1002/cncr.31243
  • Kurtz DM *, Scherer F *, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Duhrsen U, Huttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA: Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol, 2018: JCO2018785246-JCO2018785246. : http://dx.doi.org/10.1200/JCO.2018.78.5246 (in Druck)
  • Lee JR, Appelmann I, Miething C, Shultz TO, Ruderman D, Kim D, Mallick P, Lowe SW, Wang SX: Longitudinal Multiplexed Measurement of Quantitative Proteomic Signatures in Mouse Lymphoma Models Using Magneto-Nanosensors. Theranostics, 2018; 8 (5): 1389-1398. : http://dx.doi.org/10.7150/thno.20706
  • Lin CH, Wong SH, Kurzer JH, Schneidawind C, Wei MC, Duque-Afonso J, Jeong J, Feng X, Cleary ML: SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression. Cell Rep, 2018; 23 (4): 1166-1177. : http://dx.doi.org/10.1016/j.celrep.2018.03.124
  • Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Blade J, Sonneveld P: Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018; 32: 1542-1560. : http://dx.doi.org/10.1038/s41375-018-0040-1
  • Marks R, Engelhardt M, Hager S, Fullgraf H, Sudkamp NP, Herget GW: Diffuse large B cell lymphoma (DLBCL): bilateral vanishing tibiae. Ann Hematol, 2018; 97 (8): 1497-1500. : http://dx.doi.org/10.1007/s00277-018-3308-7
  • Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Muller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lubbert M, Rummelt C, Bertz H, Wasch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rosler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stolzel F, Ordemann R, Muller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kroger N, Ayuk F, Vago L, Ciceri F, Muller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dorfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Borries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socie G, Caligiuri MA, Ruggiero E, Bonini C, Hacker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med, 2018; 24 (3): 282-291. : http://dx.doi.org/10.1038/nm.4484
  • Naegele M, Kirsch M, Ihorst G, Fierz K, Engelhardt M, De Geest S: Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study. Support Care Cancer, 2018; 26 (3): 833-841. : http://dx.doi.org/10.1007/s00520-017-3897-z
  • Pankratz F, Hohnloser C, Bemtgen X, Jaenich C, Kreuzaler S, Hoefer I, Pasterkamp G, Mastroianni J, Zeiser R, Smolka C, Schneider L, Martin J, Juschkat M, Helbing T, Moser M, Bode C, Grundmann S: MicroRNA-100 Suppresses Chronic Vascular Inflammation by Stimulation of Endothelial Autophagy. Circ Res, 2018; 122 (3): 417-432. : http://dx.doi.org/10.1161/CIRCRESAHA.117.311428
  • Peeken JC, Jutzi JS, Wehrle J, Koellerer C, Staehle HF, Becker H, Schoenwandt E, Seeger TS, Schanne DH, Gothwal M, Ott CJ, Grunder A, Pahl HL: Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood, 2018; 131 (18): 2065-2073. : http://dx.doi.org/10.1182/blood-2017-10-810622
  • Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Oblander J, Pressler J, Bohm V, Bruggemann M, Wunderle L, Huttmann A, Wasch R, Beck J, Stelljes M, Viardot A, Lang F, Hoelzer D, Hofmann WK, Serve H, Weiss C, Goekbuget N, Ottmann OG, Nowak D: Genomic CDKN2A/2B deletions in adult Ph(+) ALL are adverse despite allogeneic stem cell transplantation. Blood, 2018; 131 (13): 1464-1475. : http://dx.doi.org/10.1182/blood-2017-07-796862
  • Pironi L, Konrad D, Brandt C, Joly F, Wanten G, Agostini F, Chambrier C, Aimasso U, Zeraschi S, Kelly D, Szczepanek K, Jukes A, Di Caro S, Theilla M, Kunecki M, Daniels J, Serlie M, Poullenot F, Wu J, Cooper SC, Rasmussen HH, Compher C, Seguy D, Crivelli A, Pagano MC, Hughes SJ, Guglielmi FW, Kozjek NR, Schneider SM, Gillanders L, Ellegard L, Thibault R, Matras P, Zmarzly A, Matysiak K, Van Gossum A, Forbes A, Wyer N, Taus M, Virgili NM, O'Callaghan M, Chapman B, Osland E, Cuerda C, Sahin P, Jones L, Lee ADW, Bertasi V, Orlandoni P, Izbeki F, Spaggiari C, Diez MB, Doitchinova-Simeonova M, Garde C, Serralde-Zuniga AE, Olveira G, Krznaric Z, Czako L, Kekstas G, Sanz-Paris A, Jauregui EP, Murillo AZ, Schafer E, Arends J, Suarez-Llanos JP, Shaffer J, Lal S: Clinical classification of adult patients with chronic intestinal failure due to benign disease: An international multicenter cross-sectional survey. Clin Nutr, 2018; 37 (2): 728-738. : http://dx.doi.org/10.1016/j.clnu.2017.04.013
  • Poggio T, Duyster J, Illert AL: Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas. Cancers, 2018; 10 (9): 339. : http://dx.doi.org/10.3390/cancers10090339
  • Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholoma M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kroger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R: Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med, 2018; 10 (429): ?-?. : http://dx.doi.org/10.1126/scitranslmed.aam7729
  • Rassner MP, Seidl M, Salzer U, Rajkumar SV, Epting T, Wasch R, Neumann-Haefelin E, Engelhardt M: Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature. Cl Lymph Myelom Leuk, 2018; 8 (1): e1-e7. : http://dx.doi.org/10.1016/j.clml.2017.09.019
  • Ringden O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Floisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socie G, Kroger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A: What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? J Intern Med, 2018; 283 (2): 166-177. : http://dx.doi.org/10.1111/joim.12695
  • Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M, Rezaei N: Cancer cachexia: Diagnosis, assessment, and treatment. Crit Rev Oncol Hemat, 2018; 127: 91-104. : http://dx.doi.org/10.1016/j.critrevonc.2018.05.006
  • Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kroger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A: Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol, 2018; 11 (1): 55-55. : http://dx.doi.org/10.1186/s13045-018-0598-0
  • Schanz J, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Fonatsch C, Pfeilstocker M, Nosslinger T, Valent P, Giagounidis A, Aul C, Lubbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D: Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Gene Chromosome Canc, 2018. : http://dx.doi.org/10.1002/gcc.22667 (in Druck)
  • Scheller E, Schumacher LV, Peter J, Lahr J, Wehrle J, Kaller CP, Gaser C, Kloppel S: Brain Aging and APOE epsilon4 Interact to Reveal Potential Neuronal Compensation in Healthy Older Adults. Front Aging Neurosci, 2018; 10: 74-74. : http://dx.doi.org/10.3389/fnagi.2018.00074
  • Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kroger N: Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Haematologica, 2018; 103 (2): 237-245. : http://dx.doi.org/10.3324/haematol.2017.168716
  • Schneidawind C, Jeong J, Schneidawind D, Kim IS, Duque-Afonso J, Wong SHK, Iwasaki M, Breese EH, Zehnder JL, Porteus M, Cleary ML: MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing. Blood Advances, 2018; 2 (8): 832-845. : http://dx.doi.org/10.1182/bloodadvances.2017013748
  • Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kurner A, Haas J, Greve G, Haydn T, Fulda S, Lubbert M, Ludeke S, Berg T, Sippl W, Schule R, Jung M: Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Eur J Med Chem, 2018; 144: 52-67. : http://dx.doi.org/10.1016/j.ejmech.2017.12.001
  • Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gatwood KS, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A: Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Tr, 2018; 24 (7): 1406-1414. : http://dx.doi.org/10.1016/j.bbmt.2018.04.008
  • Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K: Microenvironmental stromal cells abrogate NF-kappaB inhibitor-induced apoptosis in chronic lymphocytic leukemia. Haematologica, 2018; 103 (1): 136-147. : http://dx.doi.org/10.3324/haematol.2017.165381
  • Snowden JA, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M, Lindsay JO, Onida F, Salas A, Saccardi R, Vermeire S, Rovira M, Ricart E: Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. J Crohns Colitis, 2018; 12 (4): 476-488. : http://dx.doi.org/10.1093/ecco-jcc/jjx184
  • Stosch JM, Heumuller A, Niemoller C, Bleul S, Rothenberg-Thurley M, Riba J, Renz N, Szarc Vel Szic K, Pfeifer D, Follo M, Pahl HL, Zimmermann S, Duyster J, Wehrle J, Lubbert M, Metzeler KH, Claus R, Becker H: Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. Brit J Haematol, 2018; 182 (6): 830-842. : http://dx.doi.org/10.1111/bjh.15461
  • Thomsen AR, Aldrian C, Bronsert P, Thomann Y, Nanko N, Melin N, Rucker G, Follo M, Grosu AL, Niedermann G, Layer PG, Heselich A, Lund PG: A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. Lab Chip, 2018; 18 (1): 179-189. : http://dx.doi.org/10.1039/c7lc00832e
  • Vasu S, Kohlschmidt J, Mrozek K, Eisfeld AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE, Moore JO, Baer MR, Roboz GJ, Stone RM, Byrd JC, Carroll AJ, Bloomfield CD: Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Advances, 2018; 2 (13): 1645-1650. : http://dx.doi.org/10.1182/bloodadvances.2017015222
  • Waldschmidt JM, Keller A, Ihorst G, Grishina O, Muller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wasch R, Engelhardt M: Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica, 2018 (online). : http://dx.doi.org/10.3324/haematol.2018.189969
  • Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ: A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin, 2018; 144 (6): 1087-1095. : http://dx.doi.org/10.1007/s00432-018-2643-3
  • Waller CF, Vutikullird A, Lawrence TE, Shaw A, Liu MS, Baczkowski M, Sharma R, Barve A, Goyal P, Donnelly C, Sengupta N, Pennella EJ: A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab. Brit J Clin Pharmaco, 2018; 84 (10): 2336-2343. : http://dx.doi.org/10.1111/bcp.13689
  • Wehr C, Grotius K, Casadei S, Bleckmann D, Bode SFN, Frye BC, Seidl M, Gulsuner S, King MC, Percival MB, Pritchard CC, Walsh T, Wu D, Keel S, Salzer U: A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing. Blood, 2018; 132 (11): 1211-1215. : http://dx.doi.org/10.1182/blood-2018-03-837336
  • Wehrle A, Kneis S, Dickhuth HH, Gollhofer A, Bertz H: Endurance and resistance training in patients with acute leukemia undergoing induction chemotherapy-a randomized pilot study. Support Care Cancer, 2018. : http://dx.doi.org/10.1007/s00520-018-4396-6 (in Druck)
  • Zeiser R: Immune modulatory effects of statins. Immunology, 2018; 154 (1): 69-75. : http://dx.doi.org/10.1111/imm.12902
  • Zeiser R: Introduction to a review series on strategies to improve GVL effects. Blood, 2018; 131 (10): 1039-1039. : http://dx.doi.org/10.1182/blood-2017-11-814467
  • Zeiser R, Sarantopoulos S, Blazar BR: B-cell targeting in chronic graft-versus-host disease. Blood, 2018; 131 (13): 1399-1405. : http://dx.doi.org/10.1182/blood-2017-11-784017

Besondere wissenschaftliche Aktivitäten

Preise / Ehrungen:
  • Dr. Verena Klämbt: Albrecht-Fleckenstein-Preis, für Ihre Promotionsarbeit (AG Zeiser), 22.08.2016.

Abschlussarbeiten